Citadel Advisors
INTS icon

Citadel Advisors’s Intensity Therapeutics INTS Stock Holding History

Citadel Advisors’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,032
Closed -$50.8K – 13751
2025
Q1 		$50.8K Buy
1,032
+433
+72% +$24.1K ﹤0.01% 12297
2024
Q4 		$26.5K Buy
+599
New +$43.5K ﹤0.01% 12978

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Citadel Advisors's INTS Position: Q2 2025 in Review

Citadel Advisors sold out of Intensity Therapeutics (INTS) in Q2 2025, closing a stake of 1,032 shares — an estimated $50.8K sold.

Citadel Advisors first reported a position in INTS in Q4 2024 and held it in 2 quarters. The position peaked at $50.8K in Q1 2025. 27 funds tracked by Wall St. Rank hold INTS as of Q2 2025.

  • Citadel Advisors reported no remaining Intensity Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,032 Intensity Therapeutics shares in Q2 2025, an estimated $50.8K.
  • Citadel Advisors first reported a position in Intensity Therapeutics in Q4 2024 and held it in 2 quarters.
  • Citadel Advisors's Intensity Therapeutics position peaked at $50.8K in Q1 2025.
  • 27 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.